Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment

Clinical Cancer Research

Volumn 13, Issue 10, 2007, Pages 2928-2935

  Grigoriu, Bogdan Dragos ^a,d   Scherpereel, Arnaud ^a,b   Devos, Patrick ^c   Chahine, Bachar ^b   Letourneux, Marc ^e   Lebailly, Pierre ^f   Grégoire, Marc ^a   Porte, Henri ^b   Copin, Marie Christine ^b   Lassalle, Philippe ^a  

^a INSERM   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIV LILLE   (France)

^d GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CISPLATIN; GEMCITABINE; MESOTHELIN; OSTEOPONTIN; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; SURGICAL TECHNIQUE;

EID: 34249781709     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2144     Document Type: Article

References (45)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
2. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63-5.
3. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
4. Scherpereel A, Grigoriu BD, Conti M, et al. Soluble mesothelin-related protein in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60.
5. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-53.
6. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-73.
7. Cullen MR. Serum osteopontin levels-is it time to screen asbestos-exposed workers for pleural mesothelioma? N Engl J Med 2005;353:1617-8.
8. O'Regan AW, Serlin D, Berman JS. Asbestos exposure and serum osteopontin. N Engl J Med 2006;354:304-5.
9. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994;145:610-23.
10. Chambers AF, Wilson SM, Kerkvliet N, et al. Osteopontin expression in lung cancer. Lung Cancer 1996;15:311-23.
11. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9.
12. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6.
13. Koguchi Y, Kawakami K, Uezu K, et al. High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis. Am J Respir Crit Care Med 2003;167:1355-9.
14. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-4.
15. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res 2004;121:228-41.
16. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979;16:885-93.
17. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40.
18. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28.
19. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999;96:11531-6.
20. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5.
21. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-51.
22. Ho M, Onda M, Wang QC, et al. Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev 2006;15:1751.
23. Hellstrom I, Raycraft J, Kanan S, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006;15:1014-20.
24. Galateau-Sallé FE. Pathology of malignant mesothelioma. 1st ed. NewYork: Springer-Verlag; 2006. p. 204.
25. Rusch VW; from the International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995;108:1122-8.
26. Conover WJ, Iman RL. Analysis of covariance using the rank transformation. Biometrics 1982;38:715-24.
27. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
28. Contal C, O'Quigley J. An application of change-point methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 1999;30:253-70.
29. Mandrekar JN, Mandrekar SJ, Cha SS. Cutpoint determination methods in survival analysis using SAS®. In: SAS User Group 28, Seattle, Washington; March 30-April 2, 2003 1999. p. Paper 261-28.
30. O'Regan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev 2003;14:479-88.
31. Bautista DS, Saad Z, Chambers AF, et al. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 1996;29:231-9.
32. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
33. Boldrini L, Donati V, Dell'Omodarme M, et al. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 2005;93:453-7.
34. Donati V, Boldrini L, Dell'Omodarme M, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005;11:6459-65.
35. Hu Z, Lin D, Yuan J, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005;11:4646-52.
36. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000;81:373-90.
37. Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006;12:4225-31.
38. Shiomi K, Miyamoto H, Segawa T, et al. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 2006;97:928-32.
39. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877-81.
40. de Silva Rudland S, Martin L, Roshanlall C, et al. Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res 2006;12:1192-200.
41. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999;5:2271-7.
42. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513-21.
43. Kolb A, Kleeff J, Guweidhi A, et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther 2005;4:740-6.
44. Shimada Y, Watanabe G, Kawamura J, et al. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 2005;68:285-92.
45. Bramwell VH, Tuck AB, Wilson SM, et al. Expression of osteopontin and HGF/Met in adult soft tissue tumors. Cancer Biol Ther 2005;4:1336-41.